Basilea Pharmaceutica Forecast, price target & analysts
Basilea Pharmaceutica Target price 2025 - Analyst rating & recommendation
Basilea Pharmaceutica Classifications & Recommendation:
Basilea Pharmaceutica Price Target
| Target Price | CHF86.19 |
| Price | CHF48.70 |
| Potential |
76.98%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Basilea Pharmaceutica 2026 .
The average Basilea Pharmaceutica target price is CHF86.19.
This is
76.98%
register free of charge
CHF126.00
158.73%
register free of charge
CHF64.64
32.73%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Basilea Pharmaceutica to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Basilea Pharmaceutica stock has an average upside potential 2026 of
76.98%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 208.54 | 224.00 |
| 32.30% | 7.41% | |
| EBITDA Margin | 30.17% | 23.07% |
| 128.84% | 23.53% | |
| Net Margin | 37.21% | 20.05% |
| 461.23% | 46.11% |
9 Analysts have issued a sales forecast Basilea Pharmaceutica 2025 . The average Basilea Pharmaceutica sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Basilea Pharmaceutica EBITDA forecast 2025. The average Basilea Pharmaceutica EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Basilea Pharmaceutica Analysts have issued a net profit forecast 2025. The average Basilea Pharmaceutica net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 5.60 | 3.66 |
| 543.68% | 34.64% | |
| P/E | 13.32 | |
| EV/Sales | 2.41 |
9 Analysts have issued a Basilea Pharmaceutica forecast for earnings per share. The average Basilea Pharmaceutica EPS is
This results in the following potential growth metrics and future valuations:
Basilea Pharmaceutica...
Current Basilea Pharmaceutica Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Jul 07 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | May 20 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | May 19 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Aug 04 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Jul 08 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Jul 07 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 26 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
